Baseline characteristics of the study cohorts
| Intention-to-treat analysis | Per-protocol analysis | |||||
|---|---|---|---|---|---|---|
| Parameters | Carvedilol group (N=70) | Placebo group (N=70) | p Value | Carvedilol group (N=66) | Placebo group (N=67) | p Value |
| Age (in years) | 48.8±10.3 | 48.8±10.5 | 0.99 | 48.91±10.30 | 49.18±10.57 | 0.88 |
| Male:female | 60:10 | 59:11 | 0.81 | 56:10 | 56:11 | 0.84 |
| Ascites, n (%) | 6 (8.6) | 11 (15.7) | 0.19 | 6 (9.09) | 10 (14.93) | 0.30 |
| Total bilirubin (mg/dL)* | 2.4±1.9 | 3.2±4.9 | 0.81 | 2.5±1.9 | 3.3±5.1 | 0.77† |
| 1.8 (1.1–3.05) | 1.7 (1.25–3.2) | 1.73 (1.1–3.05) | 1.7 (1.23–3.2) | |||
| Serum albumin (mg/dL) | 3.33±0.68 | 3.24±0.66 | 0.39 | 3.32±0.69 | 3.25±0.66 | 0.56 |
| Serum creatinine (mg/dL) | 0.77±0.29 | 0.73±0.25 | 0.32 | 0.77±0.29 | 0.73±0.25 | 0.39 |
| HVPG (mm Hg) | 14.49±4.31 | 14.97±4.76 | 0.52 | 14.32±4.34 | 15.0±4.8 | 0.39 |
| CTP | 6.85±1.73 | 6.96±1.83 | 0.72 | 6.87±1.74 | 6.89±1.78 | 0.94 |
| MELD | 9.39±2.58 | 9.86±2.79 | 0.35 | 9.52±2.61 | 9.79±2.72 | 0.59 |
| Aetiology of cirrhosis | ||||||
| Hepatitis B | 5 (7.1%) | 15 (21.4%) | 0.02 | |||
| Hepatitis C | 7 (10.0%) | 8 (11.4%) | 0.78 | |||
| Ethanol | 15 (21.4%) | 18 (25.7%) | 0.55 | |||
| Cryptogenic | 34 (48.6%) | 28 (40.0%) | 0.31 | |||
| Others | 9 (12.9%) | 1 (1.4%) | 0.008 | |||
*Median with IQR along with mean±SD.
†By Mann–Whitney U test.
CTP, Child-Turcotte-Pugh score; HVPG, hepatic venous pressure gradient; MELD, model for end stage liver disease; S Alb, serum albumin; S Creat, serum creatinine; T Bil, total bilirubin.